Patents by Inventor Takasumi GOTO

Takasumi GOTO has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Therapeutic agent for cardiomyopathy, old myocardial infarction and chronic heart failure
    Patent number: 11969459
    Abstract: The present inventors have found that HMGB1 fragment peptides having a particular amino acid sequence exhibit the effects of improvement of cardiac function, inhibition of cardiomyocyte hypertrophy, inhibition of myocardial fibrosis, and promotion of angiogenesis in an animal model of dilated cardiomyopathy, that the particular HMGB1 fragment peptides also exhibit the effects of improvement of cardiac function, inhibition of cardiomegaly, inhibition of cardiomyocyte hypertrophy, inhibition of myocardial fibrosis, and promotion of angiogenesis in an animal model of ischemic cardiomyopathy caused by old myocardial infarction, and that the particular HMGB1 fragment peptides exhibit the effects of inhibition of cardiomyocyte hypertrophy and inhibition of myocardial fibrosis in an animal model of hypertensive cardiomyopathy.
    Type: Grant
    Filed: January 26, 2018
    Date of Patent: April 30, 2024
    Assignees: StemRIM Inc., OSAKA UNIVERSITY
    Inventors: Katsuto Tamai, Yoshiki Sawa, Shigeru Miyagawa, Takashi Kido, Takasumi Goto, Takehiko Yamazaki
  • Therapeutic agent for cardiomyopathy, old myocardial infarction and chronic heart failure
    Patent number: 11826401
    Abstract: The present inventors have found that HMGB1 fragment peptides having a particular amino acid sequence exhibit the effects of improvement of cardiac function, inhibition of cardiomyocyte hypertrophy, inhibition of myocardial fibrosis, and promotion of angiogenesis in an animal model of dilated cardiomyopathy, that the particular HMGB1 fragment peptides also exhibit the effects of improvement of cardiac function, inhibition of cardiomegaly, inhibition of cardiomyocyte hypertrophy, inhibition of myocardial fibrosis, and promotion of angiogenesis in an animal model of ischemic cardiomyopathy caused by old myocardial infarction, and that the particular HMGB1 fragment peptides exhibit the effects of inhibition of cardiomyocyte hypertrophy and inhibition of myocardial fibrosis in an animal model of hypertensive cardiomyopathy.
    Type: Grant
    Filed: January 26, 2018
    Date of Patent: November 28, 2023
    Assignees: STEMRIM INC., OSAKA UNIVERSITY
    Inventors: Katsuto Tamai, Yoshiki Sawa, Shigeru Miyagawa, Takashi Kido, Takasumi Goto, Takehiko Yamazaki
  • THERAPEUTIC AGENT FOR CARDIOMYOPATHY, OLD MYOCARDIAL INFARCTION AND CHRONIC HEART FAILURE
    Publication number: 20190343924
    Abstract: The present inventors have found that HMGB1 fragment peptides having a particular amino acid sequence exhibit the effects of improvement of cardiac function, inhibition of cardiomyocyte hypertrophy, inhibition of myocardial fibrosis, and promotion of angiogenesis in an animal model of dilated cardiomyopathy, that the particular HMGB1 fragment peptides also exhibit the effects of improvement of cardiac function, inhibition of cardiomegaly, inhibition of cardiomyocyte hypertrophy, inhibition of myocardial fibrosis, and promotion of angiogenesis in an animal model of ischemic cardiomyopathy caused by old myocardial infarction, and that the particular HMGB1 fragment peptides exhibit the effects of inhibition of cardiomyocyte hypertrophy and inhibition of myocardial fibrosis in an animal model of hypertensive cardiomyopathy.
    Type: Application
    Filed: January 26, 2018
    Publication date: November 14, 2019
    Inventors: Katsuto TAMAI, Yoshiki SAWA, Shigeru MIYAGAWA, Takashi KIDO, Takasumi GOTO, Takehiko YAMAZAKI